The Conversation (0)
Actinium Pharmaceuticals (NYSE:ATNM) announced that it has filed a preliminary prospectus supplement as a part of a registration statement on Form S-3 with the Securities and Exchange Commission for a rights offering to stockholders and certain participating warrant holders of record on Wednesday, February 14, 2018. As quoted in the press release: Under the proposed rights offering, Actinium …
Actinium Pharmaceuticals (NYSE:ATNM) announced that it has filed a preliminary prospectus supplement as a part of a registration statement on Form S-3 with the Securities and Exchange Commission for a rights offering to stockholders and certain participating warrant holders of record on Wednesday, February 14, 2018.
As quoted in the press release:
Under the proposed rights offering, Actinium would distribute non-transferable subscription rights to purchase 35,714,285 units at a subscription price per unit of $0.70, to its stockholders and certain participating warrant holders on the record date. The subscription rights will be exercisable for up to an aggregate of $25.0 million of units, subject to increase at the discretion of the Company, with aggregate participation to be allocated among holders on a pro rata basis if in excess of that threshold.